glp-1 conversion Market Overview: Agonists and the Obesity Market | Blog Understanding the Conversion: How Many

Individuals were excluded if they met any of the following criteria: chronic liver disease other than NAFLD, including alcohol, viral, drug-induced, autoimmune and genetic diseases, liver cirrhosis, or clinical diagnosis of hepatic decompensation (such as oesophageal varices or ascites)

doi:10.2337/diab.26.5.480 314

The improvement may reflect easing drug shortages, expanded insurance coverage and better management of side effects

They point to cumulative risk reduction across many systems

The same week those letters went out, A major telehealth platform announced a partnership with a brand-name GLP-1 manufacturer in early 2026, agreeing to shift toward branded medications and pull back most compounded GLP-1 advertising

Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review